![Superoxide Dismutase [Cu-Zn] - Pipeline Review, H1 2020- Product Image](http://www.researchandmarkets.com/product_images/11362/11362378_500px_jpg/superoxide_dismutase_[cuzn]_pipeline_review_h1_2020.jpg)
1h Free Analyst Time
Superoxide Dismutase [Cu-Zn] - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Superoxide Dismutase - Pipeline Review, H1 2020, outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2−) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.
The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. The report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease and Wilson Disease.
Furthermore, this report also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
- AL-S Pharma AG
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Apic Bio Inc
- AveXis Inc
- Biogen Inc
- Collaborative Medicinal Development LLC
- Priavoid GmbH
- Thera Neuropharma Inc
- Trucode Gene Repair Inc
- Voyager Therapeutics Inc
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
- Antisense RNAi Oligonucleotides to Inhibit Superoxide Dismutase for CNS Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AP-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- APB-102 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AVXS-301 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Oligonucleotides to Activate SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Synthetic Peptide to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TDI-186 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- THN-1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tiomolibdate choline - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tofersen sodium - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VYSOD-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VYSOD-102 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
- Featured News & Press Releases
- Oct 16, 2019: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma's phase 1 study of AP-101 for the treatment of ALS
- Oct 14, 2019: Collaborative Medicinal Development enrolls first patient in a randomized, placebo-controlled clinical trial of CuATSM for The treatment of Amyotrophic Lateral Sclerosis
- Jul 22, 2019: Apic Bio’s APB-102 receives Orphan Drug Designation from the FDA for the treatment of genetic SOD1 ALS
- Jul 01, 2019: Copper compound shows further potential as therapy for slowing ALS
- Jun 10, 2019: Collaborative Medicinal Development reports that lead drug shows dose-dependent improvement in Parkinson's disease
- May 03, 2019: Biogen reports positive data from Phase I/II study of tofersen
- May 02, 2019: Experimental drug shows promise for genetic form of ALS
- Apr 29, 2019: Voyager Therapeutics Announces New Data on VY-SOD102 at the American Society of Gene and Cell Therapy 2019 Annual Meeting
- Apr 17, 2019: Collaborative Medicinal Development wins AU$1 million grant award from FightMND
- Jan 14, 2019: Researchers report positive results from motor neurone disease trial
- Jan 07, 2019: Collaborative Medicinal Development reports that lead drug modifies ALS progression
- Dec 17, 2018: Biogen provides update on SOD1 phase I Antisense trial
- Oct 16, 2018: Voyager Therapeutics announces preclinical data for Amyotrophic Lateral Sclerosis at the Congress of the European Society of Gene and Cell Therapy
- Jul 25, 2018: Next-generation ALS drug silences inherited form of the disease in animal models
- Jul 16, 2018: Washington University’s new ALS therapy in clinical trial stage
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Information
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indication, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by AL-S Pharma AG, H1 2020
- Pipeline by Alexion Pharmaceuticals Inc, H1 2020
- Pipeline by Alnylam Pharmaceuticals Inc, H1 2020
- Pipeline by Apic Bio Inc, H1 2020
- Pipeline by AveXis Inc, H1 2020
- Pipeline by Biogen Inc, H1 2020
- Pipeline by Collaborative Medicinal Development LLC, H1 2020
- Pipeline by Priavoid GmbH, H1 2020
- Pipeline by Thera Neuropharma Inc, H1 2020
- Pipeline by Trucode Gene Repair Inc, H1 2020
- Pipeline by Voyager Therapeutics Inc, H1 2020
- Dormant Projects, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Mechanism of Actions, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AL-S Pharma AG
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Apic Bio Inc
- AveXis Inc
- Biogen Inc
- Collaborative Medicinal Development LLC
- Priavoid GmbH
- Thera Neuropharma Inc
- Trucode Gene Repair Inc
- Voyager Therapeutics Inc
